Bone marrow-derived stem cell therapy for metastatic brain cancers

Cell Transplantation

Volumn 24, Issue 4, 2015, Pages 625-630

  Kaneko, Yuji ^a   Tajiri, Naoki ^a   Staples, Meaghan ^a   Reyes, Stephanny ^a   Lozano, Diego ^a   Sanberg, Paul R ^a   Freeman, Thomas B ^a   van Loveren, Harry ^a   Kim, Seung U ^b   Borlongan, Cesar V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Brain tumor; Gene therapy; Stem cells; Transplantation

Indexed keywords

BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER REPAIR; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BRAIN METASTASIS; CANCER THERAPY; ENDOTHELIAL PROGENITOR CELL; HUMAN; NERVOUS SYSTEM INFLAMMATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL THERAPY; BONE MARROW CELL; BRAIN NEOPLASMS; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM;

CYTOKINE; MICRORNA;

ANIMALS; BLOOD-BRAIN BARRIER; BONE MARROW CELLS; BRAIN NEOPLASMS; CELL- AND TISSUE-BASED THERAPY; CYTOKINES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICRORNAS;

EID: 84927631755     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368914X685096     Document Type: Review

References (46)

1. Abbott, N. J.; Ronnback, L.; Hansson, E. Astrocyteendothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci. 7(1):41–53; 2006.
2. Antonucci, I.; Stuppia, L.; Kaneko, Y.; Yu, S.; Tajiri, N.; Bae, E. C.; Chheda, S. H.; Weinbren, N. L.; Borlongan, C. V. Amniotic fluid as a rich source of mesenchymal stromal cells for transplantation therapy. Cell Transplant. 20(6):789–795; 2011.
3. Aragon-Ching, J. B.; Zujewski, J.A.. CNS metastasis: An old problem in a new guise. Clin. Cancer Res. 13(6):1644– 1647; 2007.
4. Bao, Q.; Zhao, Y.; Niess, H.; Conrad, C.; Schwarz, B.; Jauch, K. W.; Huss, R.; Nelson, P. J.; Bruns, C. J. Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Stem Cells Dev. 21(13):2355–2363; 2012.
5. Becerra, S. P.; Notario, V. The effects of PEDF on cancer biology: Mechanisms of action and therapeutic potential. Nat. Rev. Cancer 13(4):258–271; 2013.
6. Bernardo, G.; Cuzzoni, Q.; Strada, M. R.; Bernardo, A.; Brunetti, G.; Jedrychowska, I.; Pozzi, U.; Palumbo, R. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from nonsmall-cell lung cancer: A phase II study. Cancer Invest. 20(3): 293–302; 2002.
7. Biswas, S. K.; Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 11(10):889–896; 2010.
8. Borlongan, C. V.; Lind, J. G.; Dillon-Carter, O.; Yu, G.; Hadman, M.; Cheng, C.; Carroll, J.; Hess, D. C. Bone marrow grafts restore cerebral blood flow and blood brain barrier in stroke rats. Brain Res. 1010(1–2):108–116; 2004.
9. Chiou, G. Y.; Chien, C. S.; Wang, M. L.; Chen, M. T.; Yang, Y. P.; Yu, Y. L.; Chien, Y.; Chang, Y. C.; Shen, C. C.; Chio, C. C.; Lu, K. H.; Ma, H. I.; Chen, K. H.; Liu, D. M.; Miller, S. A.; Chen, Y. W.; Huang, P. I.; Shih, Y. H.; Hung, M. C.; Chiou, S. H. Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. Mol. Cell 52(5):693–706; 2013.
10. Deeken, J. F.; Loscher, W. The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin. Cancer Res. 13(6):1663–1674; 2007.
11. Dejana, E. Endothelial cell-cell junctions: Happy together. Nat. Rev. Mol. Cell Biol. 5(4):261–270; 2004.
12. Diaz-Flores, L.; Gutierrez, R.; Varela, H. Angiogenesis:An update. Histol. Histopathol. 9(4):807–843; 1994.
13. Eisen, T.; Marais, R.; Affolter, A.; Lorigan, P.; Robert, C.; Corrie, P.; Ottensmeier, C.; Chevreau, C.; Chao, D.; Nathan, P. D.; Jouary, T.; Harries, M.; Negrier, S.; Montegriffo, E.; Ahmad, T.; Gibbens, I.; James, M. G.; Strauss, U. P.; Prendergast, S.; Gore, M.E.. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: Phase I and open-label phase II studies. Br. J. Cancer 105(3):353–359; 2011.
14. Fidler, I. J. The role of the organ microenvironment in brain metastasis. Semin. Cancer Biol. 21(2):107–112; 2011.
15. Fidler, I. J.; Balasubramanian, K.; Lin, Q.; Kim, S. W.; Kim, S. J. The brain microenvironment and cancer metastasis. Mol. Cells 30(2):93–98; 2010.
16. Finger, E. C.; Giaccia, A. J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 29(2):285–293; 2010.
17. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82(1):4–6; 1990.
18. Fujita, A.; Fukuoka, S.; Takabatake, H.; Tagaki, S.; Sekine, K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 59(4): 291–295; 2000.
19. Gerstner, E. R.; Fine, R. L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. J. Clin. Oncol. 25(16):2306–2312; 2007.
20. Groothuis, D. R.; Vriesendorp, F. J.; Kupfer, B.; Warnke, P. C.; Lapin, G. D.; Kuruvilla, A.; Vick, N. A.; Mikhael, M. A.; Patlak, C. S. Quantitative measurements of capillary transport in human brain tumors by computed tomography. Ann. Neurol. 30(4):581–588; 1991.
21. Heath, V. L.; Bicknell, R. Anticancer strategies involving the vasculature. Nat. Rev. Clin. Oncol. 6(7):395–404; 2009.
22. Jain, R.K.. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58–62; 2005.
23. Korfel, A.; Oehm, C.; von Pawel, J.; Keppler, U.; Deppermann, M.; Kaubitsch, S.; Thiel, E., Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. A multicentre phase II study. Eur. J. Cancer 38(13):1724–1729; 2002.
24. Lee, J. S.; Murphy, W. K.; Glisson, B. S.; Dhingra, H. M.; Holoye, P. Y.; Hong, W. K. Primary chemotherapy of brain metastasis in small-cell lung cancer. J. Clin. Oncol. 7(7):916–922; 1989.
25. Liebner, S.; Fischmann, A.; Rascher, G.; Duffner, F.; Grote, E. H.; Kalbacher, H.; Wolburg, H. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 100(3):323–331; 2000.
26. Lowe, D. B.; Storkus, W. J. Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy 3(10):1265–1274; 2011.
27. Menge, T.; Zhao, Y.; Zhao, J.; Wataha, K.; Gerber, M.; Zhang, J.; Letourneau, P.; Redell, J.; Shen, L.; Wang, J.; Peng, Z.; Xue, H.; Kozar, R.; Cox, Jr., C. S.; Khakoo, A. Y.; Holcomb, J. B.; Dash, P. K.; Pati, S. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci. Transl. Med. 4(161):150-161; 2012.
28. Metz, M. Z.; Gutova, M.; Lacey, S. F.; Abramyants, Y.; Vo, T.; Gilchrist, M.; Tirughana, R.; Ghoda, L. Y.; Barish, M. E.; Brown, C. E.; Najbauer, J.; Potter, P. M.; Portnow, J.; Synold, T. W.; Aboody, K. S. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: Implications for clinical use. Stem Cells Transl. Med. 2(12): 983–992; 2013.
29. Palmieri, D.; Chambers, A. F.; Felding-Habermann, B.; Huang, S.; Steeg, P. S. The biology of metastasis to a sanctuary site. Clin. Cancer Res. 13(6):1656–1662; 2007.
30. Papadopoulos, M. C.; Saadoun, S.; Davies, D. C.; Bell, B. A. Emerging molecular mechanisms of brain tumour oedema. Br. J. Neurosurg. 15(2):101–108; 2001.
31. Patel, S. P.; Kim, K. B.; Papadopoulos, N. E.; Hwu, W. J.; Hwu, P.; Prieto, V. G.; Bar-Eli, M.; Zigler, M.; Dobroff, A.; Bronstein, Y.; Bassett, R. L.; Vardeleon, A. G.; Bedikian, A.Y. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 21(4):357–363; 2011.
32. Persidsky, Y.; Ramirez, S. H.; Haorah, J.; Kanmogne, G. D. Blood–brain barrier: Structural components and function under physiologic and pathologic conditions. J. NeuroImmune Pharmacol. 1(3):223–236; 2006.
33. Qian, C. N.; Huang, D.; Wondergem, B.; Teh, B. T. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 115(10 Suppl):2282–2289; 2009.
34. Rosner, D.; Nemoto, T.; Lane, W. W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58(4):832–839; 1986.
35. Saito, M.; Schetter, A. J.; Mollerup, S.; Kohno, T.; Skaug, V.; Bowman, E. D.; Mathe, E. A.; Takenoshita, S.; Yokota, J.; Haugen, A.; Harris, C. C. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: A retrospective analysis of three cohorts. Clin. Cancer Res. 17(7):1875–1882; 2011.
36. Schetter, A. J.; Heegaard, N. H.; Harris, C.C.. Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31(1):37–49; 2010.
37. Schwartzentruber, D. J.; Lawson, D. H.; Richards, J. M.; Conry, R. M.; Miller, D. M.; Treisman, J.; Gailani, F.; Riley, L.; Conlon, K.; Pockaj, B.; Kendra, K. L.; White, R. L.; Gonzalez, R.; Kuzel, T. M.; Curti, B.; Leming, P. D.; Whitman, E. D.; Balkissoon, J.; Reintgen, D. S.; Kaufman, H.; Marincola, F. M.; Merino, M. J.; Rosenberg, S. A.; Choyke, P.; Vena, D.; Hwu, P., Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22):2119–2127; 2011.
38. Seol, H. J.; Jin, J.; Seong, D. H.; Joo, K. M.; Kang, W.; Yang, H.; Kim, J.; Shin, C. S.; Kim, Y.; Kim, K. H.; Kong, D. S.; Lee, J. I.; Aboody, K. S.; Lee, H. J.; Kim, S. U.; Nam, D. H. Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Lett. 311(2):152–159; 2011.
39. Studeny, M.; Marini, F. C.; Champlin, R. E.; Zompetta, C.; Fidler, I. J.; Andreeff, M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62(13):3603–3608; 2002.
40. Tu, T. J.; Ma, M. W.; Monni, S.; Rose, A. E.; Yee, H.; Darvishian, F.; Polsky, D.; Berman, R. S.; Shapiro, R. L.; Pavlick, A. C.; Mazumdar, M.; Osman, I. A high proliferative index of recurrent melanoma is associated with worse survival. Oncology 80(3–4):181–187; 2011.
41. Wehbe, H.; Henson, R.; Meng, F.; Mize-Berge, J.; Patel, T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 66(21):10517–10524; 2006.
42. Weidner, N., Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147(1):9–19; 1995.
43. Yi, B. R.; Kim, S. U.; Kim, Y. B.; Lee, H. J.; Cho, M. H.; Choi, K. C. Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. Oncol. Rep. 27(6):1823–1828; 2012.
44. Yonemori, K.; Tsuta, K.; Ono, M.; Shimizu, C.; Hirakawa, A.; Hasegawa, T.; Hatanaka, Y.; Narita, Y.; Shibui, S.; Fujiwara, Y. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116(2):302–308; 2010.
45. Zhang, J. H.; Badaut, J.; Tang, J.; Obenaus, A.; Hartman, R.; Pearce, W. J. The vascular neural network–A new paradigm in stroke pathophysiology. Nat. Rev. Neurol. 8(12):711–716; 2012.
46. Zhang, Z.; Chen, G.; Cheng, Y.; Martinka, M.; Li, G. Prognostic significance of RUNX3 expression in human melanoma. Cancer 117(12):2719–2727; 2011.